Alterity says FDA confirmed registrational path for ATH434 in MSAJul 30Regulatory decisionAlterity TherapeuticsATH434
Alterity registers open-label extension for ATH434 in French MSA patientsJul 28Trial updateAlterity TherapeuticsATH434
Alterity Therapeutics CEO to attend BTIG Biotechnology Conference 2026Jul 21PeopleAlterity Therapeutics
Alterity gets FDA meeting minutes backing Phase 3 path for ATH434 in MSAJul 7Regulatory decisionAlterity TherapeuticsATH434
Sign inSign in